KRAS-genotype dependent gene expression pattern in colorectal cancer

ABSTRACT: Colorectal cancer (CRC) is still one of the most common causes of cancer-related death worldwide (World Health Organization, Fact sheet NM-BM-0297, October 2011). Though, therapeutic options improved over the past years, the prognosis of metastatic colorectal cancer (mCRC) remains poor with a median survival of 18-21 months. Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are used for the palliative treatment of metastatic colorectal cancer (mCRC) carrying a KRAS-wildtype. Among the tumors with a KRAS-wildtype, only 35% respond, and alterations of other signaling molecules and pathways modulate therapeutic response. In this study we analyzed the effect of KRAS-mutations on intracellular signaling cascades to find new therapeutic approaches for patients with mCRC

ORGANISM(S): Homo sapiens

SUBMITTER: Christoph RM-CM-6cken 

PROVIDER: E-GEOD-38026 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress